Inhaled drug shows promise for rare lung disease combination
A therapeutic principle rooted in decades of pulmonary vascular research is entering a new stage of clinical development. The investigational inhaled drug mosliciguat, a soluble guanylate cyclase (sGC) activator, has produced marked and consistent effects in a randomized phase 2 study involving patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), one of the…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
A protein-degradation mechanism opens a new treatment route for an inherited arrhythmia
United Kingdom
-
Beyond movement, the cerebellum may contribute to the anticipation of rewards
United Kingdom
-
A major risk of breast cancer screening may have been overestimated for decades
United States
-
That fresh cleaning smell could be filling your home with nanoparticles
United States
-
Dogs support police officers with PTSD
United Kingdom
-
The higher your body fat percentage, the less accurate your smartwatch is at measuring calories burned
United Kingdom
-
REM sleep paradox: Dreaming may drain the brain’s energy even as fuel supply rises
United States
-
Getting paid to vape? Researchers say that's a dangerous combination
United Kingdom